DRUG · Bright Minds Biosciences Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | - | - | - | - |
| SG&A | - | - | - | - |
| Total Operating Expenses | - | - | - | - |
| D&A | - | - | - | - |
| Operating Income | - | - | - | - |
| Interest Expense | - | - | - | - |
| Income Tax | - | - | - | - |
| Net Income | - | - | - | - |
| EPS - Basic | - | - | - | - |
| EPS - Diluted | - | - | - | - |
Balance Sheet
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash & Equivalents | - | - | - | - |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | - | - | - | - |
| Current Assets | - | - | - | - |
| Total Assets | - | - | - | - |
| Current Liabilities | - | - | - | - |
| Long-term Debt | - | - | - | - |
| Total Liabilities | - | - | - | - |
| Stockholders' Equity | - | - | - | - |
| Retained Earnings | - | - | - | - |
Cash Flow
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - |
| Investing Cash Flow | - | - | - | - |
| Financing Cash Flow | - | - | - | - |
| CapEx | - | - | - | - |
| Free Cash Flow | - | - | - | - |
Ratios
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | - | - | - | - |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | - | - | - | - |
| Return on equity | - | - | - | - |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | - | - | - | - |
| Quick ratio | - | - | - | - |
| Cash ratio | - | - | - | - |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | - | - | - | - |
| Equity multiplier | - | - | - | - |
| Liabilities / Assets | - | - | - | - |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - |
| Net income growth (YoY) | - | - | - | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | - | - | - | - |
Stability scores
Piotroski F-score
FY 2024 · 9-point quality
0/9
Weak
- -Net income positive
- -Operating cash flow positive
- -ROA improved YoY
- -Cash flow > net income
- -Long-term debt decreased
- -Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BRIGHT MINDS BIOSCIENCES INC. against the 5 most active filers in the same SIC group.